Wireless, Transdermal Continuous Glucose Monitoring System Developed for Diabetics

The company is also developing a needle-free Prelude SkinPrep system as a platform technology for enhanced skin permeation for transdermal drug delivery of a wide range of products.

Echo Therapeutics has announced a consulting agreement with Hayden IR to develop and implement a strategic investor relations campaign. Hayden IR has offices in New York, NY; Phoenix, AZ; Minneapolis, MN; and San Diego, CA; (USA); it provides a comprehensive range of investor relations services. The company drives market recognition, and creates and sustains competitive advantages for more than 100 micro- and small-cap companies. Hayden delivers expertise and professionalism in areas such as investor management, relationship building, awareness campaigns, online presence, and corporate identity.

Jeffrey Stanlis, partner at Hayden IR, commented, "Echo Therapeutics is poised to provide proven, much sought after needle-free, continuous and painless solutions for the monitoring of glucose levels, and the company's skin permeation platform technology holds significant potential beyond the large diabetes and critical care markets. Other companies, with more limited offerings relying on needle technologies, are valued at robust enterprise value to [Earnings Before Interest, Taxes, Depreciation and Amortization] EBITDA multiples, while the market has not yet afforded Echo Therapeutics any premium despite the impressive technology and tremendous market potential Echo has developed. Hayden IR believes this represents a unique and compelling investment opportunity and we are excited to share this story with our database of contacts."

Related Links:
Echo Therapeutics
Hayden IR
University of Georgia